» Articles » PMID: 31997769

Interplay Between Inflammation and Cancer

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2020 Jan 31
PMID 31997769
Citations 120
Authors
Affiliations
Soon will be listed here.
Abstract

During the 19th century, for the first time, the linkage between inflammation and cancer was established. Inflammatory microenvironment is an essential component of the tumor microenvironment. Chronic inflammation due to persistent infection due to the microbes, viruses, helminths or constant exposure to non-infectious factors like smoke, silica or asbestos eventually might result in carcinogenesis. In tumor microenvironment, various inflammatory cells such as T lymphocytes (occasionally B cells), dendritic cells, macrophages, monocytes, neutrophils and natural killer (NK) cells are present. As a mediator of immune surveillance and host defense TRAIL cytokines are produced which upon binding with death receptors (DRs) initiate a cascade of apoptotic pathways. Anti-inflammatory drugs such as aspirin, celecoxib, diclofenac, diflunisal and ibuprofen etc. are being used against cancer, indicating the interplay between both the mechanisms. A deeper understanding of common pathways implicated between both the inflammation and cancer may pave the way to fight against both of these deleterious ailments.

Citing Articles

ZNF385A was identified as a novel colorectal cancer-related functional gene by analysis of the interaction and immune characteristics of oxidative stress and the inflammatory response.

Guo Y, Shang S, Liang L, Liu E Discov Oncol. 2025; 16(1):290.

PMID: 40064736 PMC: 11893970. DOI: 10.1007/s12672-025-02024-1.


Deciphering the metabolic landscape of colorectal cancer through the lens of AhR-mediated intestinal inflammation.

Swain J, Preeti , Mohanty C, Bajoria A, Patnaik S, Ward Gahlawat A Discov Oncol. 2025; 16(1):275.

PMID: 40053174 PMC: 11889322. DOI: 10.1007/s12672-025-01949-x.


Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.

Park M, Choi J, Maharub Hossain Fahim M, Asevedo E, Nurkolis F, Ribeiro R Front Pharmacol. 2025; 16:1504618.

PMID: 40034825 PMC: 11872924. DOI: 10.3389/fphar.2025.1504618.


HDAC3: A Multifaceted Modulator in Immunotherapy Sensitization.

Han R, Luo Y, Gao J, Zhou H, Wang Y, Chen J Vaccines (Basel). 2025; 13(2).

PMID: 40006729 PMC: 11860249. DOI: 10.3390/vaccines13020182.


Biomarkers of inflammation and colorectal cancer risk.

Li Y, Luo Y, Ran Y, Lu F, Qin Y Front Oncol. 2025; 15:1514009.

PMID: 39980561 PMC: 11839431. DOI: 10.3389/fonc.2025.1514009.